Omixon at This Year’s BSHI Conference

Arnold Feher and Tim Hague attended the BSHI conference in Manchester. There was a very interesting series of talks about the state of transplantation in the UK, plus a trade show, poster exhibition and some lunchtime presentations from the corporate sponsors concentrating on the use of NGS for HLA....

 

Read more

Cancer Biomarkers

When tackling any disease, the first step is to learn what signals its presence and what else these signs can mean. In discussing cancer, these signs are referred to as cancer biomarkers. Some organisations define a biomarker as a molecule that the cancerous tumor has secreted into the body,...

 

Read more

Omixon Launches Holotype HLA™ for NGS-based HLA Genotyping

Omixon announces the launch of Omixon Holotype HLA™ – a combination Assay and Software product that leverages the power of Next Generation Sequencing (NGS), for use on the Illumina® MiSeq sequencing platform. The assay and software have been optimized through cohesive collaboration with the Monos lab at The Children’s...

 

Read more

Omixon Celebrates a Successful EFI 2014

Omixon took a team of 8 to the 28th EFI (European Histocompatibility and Immunogenetics) Conference, held in Stockholm.  Omixon’s “A Team” of defenders (science nerds), midfielders (marketing bods) and strikers (sales weenies) were superbly captained by the indefatigable Craig Funnell (Director of Sales and Marketing), and brought super-sub Attila...

 

Read more

Omixon Target Release Notes 1.9.1

We are happy to let you know that a new version of Omixon Target is now available, including updated features and further improvements. Feel free to download the new version using the plugin on our website. When installing, select the ‘upgrade’ option to renew an existing installation.  If you have...

 

Read more